CALL FOR PAPERS: Special Issue on Ultrahigh Field Magnetic Resonance

Scaling the mountains – what lies above 7 Tesla?

The progress of ultrahigh field magnetic resonance (UHF-MR) provides meaningful technologies for the advancement of biomedical and diagnostic MRI. With 7 T human MRI now in the clinic, there is increasing interest in exploring yet higher magnetic field strengths. This includes pioneering reports on 9.4, 10.5 or 11.7 T MRI which opens a path to even higher fields.

Recognizing this momentum MR science has already taken an even more ambitious step into the future, which envisions human MR at 14 and at 20 T. There are considerable technical and practical challenges – and expense – in doing so, especially above 12 T due to the implementation of alternative superconductor technologies. Each step upward will require rigorous technical and in vivo studies, and the route has to be tested by those who adapt the technology, but recent experience at 7 T shows that such efforts will be worthwhile. What are the expected benefits that will come from this? Will climbing into higher field strengths broaden the horizons of MR applications? Will the clinical indications where 7 T has been showing benefit compared to 3 T, such as epilepsy lesion detection, diagnosis of neurodegenerative, neuroinflammatory disorders or assessment of musculoskeletal diseases, show yet further benefit from the higher field? Would indications where it is believed that clinical benefits are just sub-threshold with 7 T MRI become clinically relevant at these higher fields? Can neuroscience make giant strides towards deciphering the human brain by bridging the gap between histology, neurochemistry, neurobiology and in vivo MRI? Will we learn to make more sense of the terrain we currently inhabit at 7 T and lower fields, and better interpret the biological, physiological and metabolic meaning of the imaging findings and data we take at higher fields. Are there safety implications, both for the subject and the staff, and how can these be addressed? What are the approaches and recent progress in overcoming barriers governed by material sciences and in reducing the expense of these higher field systems?

Realizing these opportunities, MAGMA is planning a special issue on human UHF-MR to be published in its 2nd volume of 2023. The special issue is designed to balance methods oriented developments, novel technologies and technical solutions of ultrahigh (B0=7-10.5 T) and extreme-field MR (B0>10.5 T) together with applications and research promises. For this purpose we wish to encourage studies which benchmark UHF-MR innovations versus today’s standards and welcome studies exploring new clinical and neuroscientific territory with cutting edge technologies. The special issue offers unique space for new concepts and applications which might be of preliminary nature, but continue to motivate new research. It is our goal that these topics will bridge disciplinary boundaries and will stimulate the imaging communities to throw further weight behind the solution of unsolved technical problems and unmet clinical needs en route to what lies above 7 T.

We invite manuscripts (short communications, data in brief as well as full-length manuscripts) on topics pertinent to the scope of the Special Issue. In order to meet the timeline, papers should be submitted not later than October 1st, 2022 (and preferably sooner) using the normal submission procedures on the web. Authors should indicate in their cover letter that the manuscript is submitted "For inclusion in the Special Issue on UHF-MR”.

MAGMA special issues are widely read and heavily referenced. This is your chance to think outside of the box and to get your latest and best work at 7.0 T and higher published in a timely manner. We are looking forward to receiving your manuscripts.

MAGMA Editor-in-Chief
David G. Norris

Guest Editors of the Special Issue
Saskia Bollmann, Brisbane 
Elena Kleban, Bern (Nominated by Early Career researchers ad hoc Committee of ESMRMB)
Thoralf Niendorf, Berlin
Rita Schmidt, Rehovot  
Christopher Wiggins, Maastricht